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Key points: 
 
• Genomic deletions of CDKN2A/2B are a new independent prognostic risk factor 
in adult Ph+ ALL 
 
Abstract 
We investigated the role of copy number alterations to refine risk stratification in adult 
Philadelphia chromosome positive (Ph)+ ALL treated with tyrosine kinase inhibitors 
(TKI) and allogeneic stem cell transplantation (aSCT). 97 Ph+ ALL patients (median 
age 41 years, range 18-64 years) within the prospective multicenter GMALL studies 
06/99 (n=8) and 07/2003 (n=89) were analysed. All patients received TKI and aSCT in 
first complete remission (CR1). Copy number analysis was performed with SNP arrays 
and validated by multiplex ligation-dependent probe amplification (MLPA). The 
frequencies of recurrently deleted genes were: IKZF1, 76%, CDKN2A/2B, 45%, PAX5, 
43%, BTG1, 18%, EBF1, 13%, ETV6, 5%, RB, 14%. In univariate analyses, the 
presence of CDKN2A/2B deletions had a negative impact on all endpoints: overall 
survival (p=0.023), disease free survival (p=0.012) and remission duration (p=0.036). 
The negative predictive value of CDKN2A/2B deletions was retained in multivariable 
analysis along with other factors such as timing of TKI therapy, intensity of conditioning, 
achieving remission after induction phase I and BTG1 deletions. We therefore 
conclude that acquired genomic CDKN2A/2B deletions identify a subgroup of Ph+ ALL 
patients, who have an inferior prognosis despite aSCT in CR1. Their poor outcome 
was attributable primarily to a high relapse rate after aSCT.  
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Introduction 
Philadelphia chromosome positive (Ph+) ALL is characterized by a reciprocal 
translocation that fuses the ABL1 oncogene on chromosome 9 to a breakpoint cluster 
region (BCR) on chromosome 22. Ph+ ALL is the largest genetically defined subtype in 
adult ALL and is traditionally considered the subtype with the worst prognosis. 
Substantial improvements in response and long-term survival have been achieved by 
combining tyrosine kinase inhibitors (TKI) such as Imatinib or Dasatinib with intensive 
chemotherapy regimen.1-6 However, allogeneic stem cell transplantation (aSCT) in first 
complete remission (CR1) is the only reliable curative post-remission therapy in 
adults.7 Following combined treatment strategies with TKIs, cytotoxic chemotherapy 
and aSCT, long-term disease-free survival ranges from 30 - 69%,4,5,8,9 with 
transplant-related mortality (TRM) and relapse contributing approximately equally to 
treatment failure. This heterogeneity of prognosis suggests additional biologic 
pathomechanisms other than the BCR-ABL driver lesion that have not been 
systematically determined. This is further exemplified by the differences between adult 
and pediatric Ph+ ALL, with the majority of children appearing to be cured by combined 
TKI and chemotherapy, even without aSCT.10 To this end, microarray-based 
genome-wide profiling studies have revealed numerous submicroscopic genetic 
lesions in patients with BCR-ABL negative as well as Ph+ ALL. The prognostic 
relevance of these alterations have been studied extensively in pediatric and to a 
lesser degree in adult ALL.11-15 Most recurring genomic abnormalities involve single 
genes, which are implicated in B-cell differentiation, cell survival, or cell-cycle 
progression, such as CDKN2A/2B, IKZF1, PAX5, ETV6, RB1, BTG1, EBF1, and 
therefore have been suggested to play a role in leukemogenesis. Deletions of IKZF1, 
which encodes the lymphoid transcription factor Ikaros, and of CDKN2A/2B and PAX5 
genes have received particular attention due to their high frequency particularly in Ph+ 
ALL. IKZF1 deletions have been linked to an inferior outcome in most pediatric ALL 
studies16-18 as well as in studies involving adult and adolescent Ph negative BCP-ALL19 
and adult Ph+ ALL,12 respectively. However, because these associations with 
prognosis were significant only in univariate but not in multivariate analyses in several 
initial studies, the additional prognostic value of IKZF1 deletions has been debated.20,21 
Nevertheless, also subsequent investigations taking into account leukemia subtype 
and therapeutic context have retained IKZF1 deletions as an unfavourable prognostic 
marker.22,23  
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The prognostic relevance of IKZF1, CDKN2A/2B, PAX5 and other recurrent genomic 
aberrations in the setting of allogeneic SCT for adult patients with Ph+ ALL has hardly 
been examined. To this end, in adult Ph+ ALL, the presence of additional cytogenetic 
lesions in adult Ph+ ALL patients was shown to negatively influence prognosis in the 
therapeutic setting of TKI combined with chemotherapy24 or even beyond aSCT.25 
Furthermore, TKI resistance in this patient group has been linked to ABL1 kinase 
mutations and/or the presence of genomic deletions such as IKZF1 or 
CDKN2A/2B.26,27 Kim et al. recently investigated the prognostic relevance of IKZF1 
deletions in adult Ph+ ALL patients in a uniform aSCT setting and combined treatment 
with Imatinib. There, the investigators could show a trend for higher incidence of 
relapse in patients with IKZF1 deletions, albeit not reaching significance nor 
independent statistical power in multivariate analyses.28 We therefore addressed the 
question whether in adult Ph+ ALL the putative adverse prognosis conferred by IKZF1 
and/or other frequent microdeletions of genes associated with B-cell development can 
be overcome by aSCT, and whether these genomic alterations are predictive of 
outcome independently of, or in addition to, levels of minimal residual disease (MRD) 
during front-line therapy. By SNP microarray analysis and validation with multiplex 
ligation-dependent probe amplification (MLPA), we examined adult Ph+ ALL samples 
obtained at initial diagnosis from n=97 patients who received Imatinib as part of their 
treatment and underwent aSCT in CR1, and correlated the genomic data with outcome 
after aSCT.  
 
Patients and Methods 
Patients 
The molecular and clinical outcome analyses in this study were carried out 
retrospectively on bone marrow (n=61) or peripheral blood (n=35), unknown (n=1) 
samples from initial diagnosis of n=97 adult patients with PH+ ALL who were enrolled 
in the GMALL studies 06/99 (NCT00199056) (n=8) and 07/2003 (NCT00198991) 
(n=89) from October 2001 to November 2009. Molecular analyses were carried out 
with written informed consent of all patients, approved by the Medical Ethics 
Committee of the University of Frankfurt a.M., Germany in accordance with the 
Declaration of Helsinki. Characteristics of the 97 retrospectively analyzed patients are 
summarized in Table 1. All patients received Imatinib and underwent aSCT within the 
study protocols.29 A detailed description of therapy is summarized by Wassmann et al.6 
Briefly, all patients in the current study received an identical backbone of 
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chemotherapy consisting of a pre-phase with Dexamethasone and Cyclophosphamide, 
followed by induction chemotherapies consisting of induction phase 1 (=IP1, weeks 1 
to 3, containing Dexamethasone, Vincristine, Daunorubicine and PEG-Asparaginase) 
followed by induction phase 2 (=IP2, weeks 4 to 6, containing Cyclophosphamide, 
Cytarabine and 6-mercaptopurin). Consolidation consisted of Dexamethasone, 
Vindesine, high-dose Methotrexate (MTX), Etoposide and Cytarabine. Central nervous 
system prophylaxis consisted of intrathecal injection of MTX (15 mg) once during 
pre-phase and thrice during IP2 and a single intrathecal administration of MTX 15 mg, 
Cytarabine 40 mg and Dexamethasone 4 mg after consolidation 1. Patients achieving 
CR in IP1 also received a prophylactic cranial irradiation of 24 Gy parallel to IP2.  
Patients in this current study received Imatinib 600 mg once a day in three different 
schedules: In the cohort defined as "Imatinib late", 5 patients received Imatinib in an 
alternating schedule to chemotherapy either after IP2 and after the consolidation 
phase. The remaining 23 patients started Imatinib treatment after IP1. The cohort 
defined as "Imatinib early" started Imatinib directly after the pre-phase in parallel to IP1. 
All patients received aSCT in CR1. The recommendation within the GMALL protocol 
was to use a myeloablative conditioning (MAC) regimen (TBI-based) for patients 
undergoing allogeneic stem cell transplantation. In the current study cohort, the 
following regimen were defined as MAC: TBI-based regimen with 12 Gy / 
Cyclophosphamide (n=40), TBI 12 Gy / Etoposide (n=27), TBI 12 Gy / Etoposide / 
Cyclophosphamide (n=4), TBI 10 Gy / Cyclophosphamide (n=2), TBI 8 Gy / 
Cyclophosphamide (n=2), TBI 8 Gy / Fludarabine (n=2), TBI 8 Gy / Cyclophosphamide 
/ Fludarabine (n=1). The following regimen were considered as reduced intensity 
conditioning (RIC): Fludarabine based regimen such as Fludarabine / Busulfan / 
Melphalan (n=2), Fludarabine / Busulfan (n=2), Fludarabine / Melphalan (n=1), 
Fludarabine / Busulfan / Thiotepa (n=3), Treosulfan-based regimen such as Treosulfan 
/ Cyclophosphamide / Etoposide (n=7) or Treosulfan / Fludarabine (n=1) or TBI-based 
regimen with 4 Gy TBI / Cyclophosphamide (n=1) and 2 Gy / Fludarabine (n=1), n.a. 
(n=1).  
 
Single nucleotide polymorphism microarray (SNP-A) analysis 
500 ng of genomic DNA per sample from leukemic blasts were processed according to 
the Genome Wide Human SNP 6.0 Array protocol (Affymetrix, Santa Clara, CA). 
Genotyping files were imported into the CNAG 3.3 software to perform allele-specific 
copy number analysis with anonymous references as previously described.30,31 Known 
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copy number polymorphisms were excluded from the data by comparison with known 
copy number polymorphisms registered in the UCSC genome browser 
http://genome.ucsc.edu/, (hg-18). Putatively acquired copy number alterations (CNAs) 
were validated in matched pair SNP 6.0 array analysis of DNA from initial diagnosis 
and full remission samples in n=11 cases.  
 
Multiplex ligation-dependent probe amplification analysis 
To further validate the presence of deletions of commonly deleted genes in ALL 
detected by SNP array, the Multiplex Ligation-dependent Probe Amplification (MLPA) 
assay SALSA MLPA P335 ALL-IKZF1 probe mix kit (MRC Holland, Amsterdam, 
Netherlands) was used according to the manufacturer’s protocol. Thereby, deletions of 
the following genes were validated: IKZF1, CDKN2A/2B, PAX5, BTG1, EBF, ETV6 
and RB. Electrophoresis and relative quantification of fluorescein-labeled amplicons 
was performed on an ABI-3130 genetic analyzer (Applied Biosystems, Carlsbad, CA). 
The resulting peak intensities were normalized to the manufacturers’ control probes 
and to normal DNA as a reference with the Coffalyser Software (MRC Holland, 
Amsterdam, Netherlands). The resulting MLPA data was combined with SNP array 
data according to the following algorithm: Homozygous deletions of the above listed 
commonly deleted genes were called if either the SNP array data called a homozygous 
deletion by hidden Markov model (HMM)31 and/or at least 2 adjacent MLPA probes 
measured an intensity ratio of <0.3. Heterozygous deletions were called if either SNP 
array data called a heterozygous deletion by HMM and/or at least 2 adjacent MLPA 
probes measured an intensity ratio of <0.7. 
 
Analysis of minimal residual disease and BCR-ABL mutations  
Analysis of MRD was performed using quantitative real-time polymerase chain 
reaction (qRT-PCR) analysis and confirmatory testing by nested PCR as previously 
described.32,33 Briefly, peripheral blood and bone marrow mononuclear cells (MNC) 
were separated by Ficoll centrifugation. Total RNA was extracted with RNA Bee 
(Ambion, Invitrogen, Darmstadt, Germany) or RNeasy (Qiagen, Hilden, Germany). 
cDNA was synthesized from 1-5µg RNA using MMLV (Promega, Mannheim, 
Germany) and random hexamers (Applied Biosystems, Darmstadt, Germany). 
Realtime PCR was performed with the Europe Against Cancer (EAC)34 primer and 
probe set for BCR-ABL and ABL1. For samples earlier than 2004, in-house primers 
were used for GAPDH and BCR-ABL as described previously.35  ABL1 or GAPDH 
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were used as housekeeping genes. Complete Molecular Response (CMR) was 
defined as BCR-ABL/ABL ratio below or equal to 10-4 or a BCR-ABL/GAPDH ratio 
below or equal to 10-6. Historically, the difference of threshold for GAPDH was defined 
due to the higher intrinsic expression of this gene by approximately 2 log.36 
Major Molecular Response (MMR) for BCR-ABL/ABL was defined as >10-4 but below 
10-3 or BCR-ABL/GAPDH >10-6 but below 10-5, “no MMR” was defined as >10-3 for 
BCR-ABL/ABL and > 10-5 for BCR-ABL/GAPDH. For calling negative MRD, the ABL 
copy number had to be at least 104  and GAPDH had to be at least 106. MRD evaluation 
was performed at least once after consolidation for 69 pts. Another 9 patients were 
evaluated before consolidation. In two patients only FISH results were available. 
These were added to the group "no MMR", because they were FISH positive.  
 
Statistical analyses 
Relapse was defined by recurrence of more than 5% lymphoblasts in the bone marrow 
(BM), peripheral blood (PB) or by the appearance of extramedullary disease after 
achieving CR. Overall survival (OS) was calculated from date of diagnosis to death of 
any cause. Disease free survival (DFS) was calculated from the time point of aSCT 
until relapse, death from any cause or development of secondary malignancy. 
Remission duration (REM) was calculated from the time point of aSCT until leukemia 
relapse. Patients were censored at last follow-up if no event of interest occurred. 
Univariate analyses of OS, DFS and REM comparing two or more groups were made 
using the log-rank test. The median duration of follow up for OS was 35 months (range 
5.4 – 114.4) and 20.5 months (range 0.6 – 108.3) for REM and DFS. Univariate 
analyses were carried out using GraphPad Prism version 6.07 for Windows (GraphPad 
Software, San Diego, CA). For multivariable analyses, Cox proportional hazards 
models were calculated for OS, DFS and REM. The following covariates were included 
into all models: IKZF1 deletion (presence versus absence), PAX5 deletion (presence 
versus absence), CDKN2A/2B deletion (presence versus absence), BTG1 deletion 
(presence versus absence), EBF1 deletions (presence versus absence), ETV6 
deletions (presence versus absence), RB1 deletions (presence versus absence), total 
number of recurrent deletions (0 or 1 versus 2 or more), age (years), sex (male versus 
female), white blood cell count (WBC) at diagnosis (<30 000/µl versus >30 000/µl), 
minimal residual disease (MRD) pre aSCT: CMR or MMR versus no MMR, 
hematologic response after induction phase 1 (IP1) (yes versus no), transcript type 
(p210 BCR-ABL versus p190 BCR-ABL), type of donor (matched unrelated donor 
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versus sibling / HLA matched versus non-matched). Imatinib schedule: Imatinib early 
(= starting with IP1) versus Imatinib late ( = start either after IP1 or alternating after IP2 
and after consolidation6, myeloablative conditioning (MAC) versus reduced intensity 
conditioning (RIC), TBI based conditioning versus non-TBI based conditioning. 
Stepwise backward elimination was performed. The entry level for effects to enter the 
model was set at 0.10. The multivariable analyses were carried out at the Institute for 
Biomedical Statistics, Medical Faculty Mannheim, Heidelberg University, Germany 
with the SAS software, release 9.2 (SAS Institute, Cary, NC). 
 
Results 
Genomewide copy number analysis and MLPA analysis of diagnostic Ph+ adult 
ALL samples 
To assess the profile of acquired copy number alterations (CNAs) of adult Ph+ ALL 
samples we analysed initial diagnostic samples from the entire cohort of n=97 patients 
with high density Affymetrix SNP 6.0 arrays. For n=11 samples, matched paired 
analysis with samples from a timepoint of complete remission as germline controls 
could be performed. However, due to the unavailability of remission or other germline 
control samples, the remaining n=86 samples were analysed with non-matched 
anonymous references according to previously established robust algorithms.30,31 This 
analysis identified a total of 830 putatively acquired CNAs corresponding to a mean 
number of 8.6 CNAs per patient. The identified lesions consisted of 578 homozygous 
or heterozygous deletions, 240 duplications or amplifications, and 12 regions of copy 
number neutral loss of heterozygosity (CNLOH). A detailed summary of all CNAs 
detected by SNP array is depicted in Supplementary tables 1-3. The most common 
recurrent CNAs detected by SNP array analysis alone consisted of the known 
recurrently deleted genes in ALL such as IKZF1 (n=72 / 74%), CDKN2A/2B (n=41 / 
42%), PAX5 (n=39 / 40%), BTG1 (n=14 / 14%), RB1 (n=13 / 13%), EBF1 (n=11 / 11%) 
and ETV6 (n=5 / 5%), (Table 2). Of note, a total of n = 40 (41%) unbalanced 
breakpoints of BCR and or ABL could be identified. The remaining bulk of recurrent 
lesions was mainly composed of whole chromosome aberrations such as deletion of 
chromosome 7 or trisomies of chromosomes 21, 4, 6, 8 and others in hyperdiploid 
samples. Due to the circumstance that with the exception of n=11 cases, all SNP array 
copy number inferrals were carried out with non-matched anonymous references, we 
validated the presence of the most common, ALL typical CNAs (IKZF1, CDKN2A/2B, 
PAX5, BTG1, RB1, EBF1 and ETV6) with multiplex ligation-dependent probe 
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amplification (MLPA) as a second molecular method. Both methods, SNP-array and 
MLPA are semiquantitative methods, so expectedly there were some deviations of 
results in few cases. However, the use of two complimentary methods allowed to apply 
a higher stringency in calling the recurrent deletions listed above. Consequently, the 
MLPA data was combined with SNP array data according to the following algorithm: 
Homozygous deletions of the above listed, 7 commonly deleted genes were called 
positive if either the SNP array data called a homozygous deletion by Hidden Markov 
Model (HMM)31 and / or at least 2 adjacent MLPA probes measured an intensity ratio of 
<0.3. Heterozygous deletions were called positive if either SNP array data called a 
heterozygous deletion by HMM and / or at least 2 adjacent MLPA probes measured an 
intensity ratio of <0.7. Using this algorithm, addition of MLPA analysis largely 
confirmed the SNP array data with the exception of single cases, which led to the 
identification of a slightly higher number of deletions of the 7 analyzed genomic regions 
by supplementation with MLPA (Table 2, right column).  
 
Correlation of recurrent genomic deletions with outcome in univariate analysis 
indicates that CDKN2A/2B, IKZF1 and BTG1 deletions are associated with 
inferior prognosis 
The results of the combined genomic analysis of the seven most commonly deleted 
genes IKZF1, CDKN2A/2B, PAX5, BTG1, EBF1, ETV6 and RB1 were used to analyse 
their relationship to clinical outcome of the adult Ph+ ALL patients in the aSCT setting. 
Univariate analysis revealed that genomic deletions of CDKN2A/2B were significantly 
associated with an inferior performance in all three endpoints OS, DFS and REM (OS: 
p=0.023, DFS: p=0.012, REM: p=0.036, Figure 1A-C). The presence of IKZF1 
deletions was associated with a trend for higher risk in OS and with significantly inferior 
outcome for DFS (p=0.045) and REM (p=0.03), (Figure 1D - F). Similarly, presence of 
deletions of all other above described commonly deleted genes mostly showed trends 
for worse performance in all three endpoints. Statistical significance was reached for 
BTG1 deletions for DFS (p=0.037) and REM (p=0.003) (Supplemental Figures 
1A-3C). 
 
Co-occurrence of common deletions but not the presence of exclusive IKZF1 
deletions alone is associated with inferior outcome  
Our analysis showed that most patients (61%) had more than one of the recurrently 
deleted genes affected in the genomes of their leukemia cells. We therefore analysed 
 11
the clinical outcome data in dependency of the number of deletions of the seven most 
recurrently deleted genes IKZF1, CDKN2A/2B, PAX5, BTG1, EBF1, ETV6 and RB. As 
depicted in Figure 2A, n=14 patients had none of these lesions, n=24 had one of the 
above deletions, n=16 had two, n=25 had three, n=15 had four, n=3 had 5 or more 
co-occurring common deletions. Increasing numbers of co-occurring recurrent 
deletions per se were significantly associated with an increased risk of events after 
aSCT (p=0.011) (Figure 2B). When dichotomized into two groups of patients with 
either 0 or one recurrent deletion versus 2 or more recurrent deletions, the latter group 
had a substantially worse outcome in all endpoints OS (p=0.018), DFS (p=0.0026) and 
REM (p=0.0017) (Figures 2C-E). Interestingly, this was also reflected in significantly 
higher numbers of leucocytes in the group with two or more recurrent deletions 
(p=0.0074) (Figure 2F).  In the light of these results we also asked whether a putative 
negative effect of IKZF1 deletions was influenced by the presence of accompanying 
lesions. This analysis showed that patients, who had IKZF1 deletions as an exclusive 
lesion out of the seven above described recurrent deletions had a significantly better 
prognosis in terms of DFS (p=0.018) and REM (p=0.026) as compared to patients who 
carried IKZF1 deletions in combination with any of the other recurrent deletions 
(Figure 3A-B). 
 
Genomic CDKN2A/2B deletions, Imatinib treatment schedule and intensity of 
conditioning are strong independent negative predictors for adult Ph+ ALL 
treated with Imatinib and aSCT 
Risk stratification in adult ALL has so far been carried out with clinical parameters such 
as age, leucocyte counts at initial diagnosis, immunophenotypic ALL subtype but also 
cytogenetic markers such as the t(9;22), t(4;11), other translocations or numeric 
chromosomal aberrations.37,38 Moreover, the time to reach CR after the initial induction 
chemotherapy has proven to be prognostically relevant.39 Expectedly, failure to reach 
CR after IP1 was highly predictive for relapse, DFS (p=0.008), REM (p<0.0001) 
(Supplemental Figure 3D-E). On the transcript level, highly sensitive and 
standardized detection of minimal residual disease (MRD) by molecular measurement 
of BCR-ABL fusion products in Ph+ ALL has evolved as an important prognostic tool to 
determine how quickly patients reach complete molecular remissions (MRD < 10-4) 
after the first induction therapy (IP1).32,39,40 In our cohort, MRD data pre SCT was 
available for n=78 patients and MRD response was not significantly associated with 
outcome regarding any of the tested endpoints (Supplemental Figure 4A-C).   
 12
Previous data had shown that addition of Imatinib to the treatment protocols of Ph+ 
ALL improved the outcome.6 Additionally, an earlier start of Imatinib within the protocol 
was associated with a higher benefit as compared to a later start of Imatinib therapy.6  
In the cohort of this current study, all patients achieved complete remission after IP2 
following treatment with Imatinib. In this context, starting Imatinib early simultaneously 
with IP1 led to significantly improved outcome for all endpoints, OS (p=0.024), DFS 
(p=0.0007) and REM (p=<0.0001) (Figure 4A-C). As all patients in this study received 
aSCT, we also asked the question of whether the intensity of conditioning had an 
impact on outcome. This analysis revealed that reduced intensity conditioning (RIC) 
was associated with poorer OS (p=0.029) and DFS (0.019) (Figure 4D-F).  
To test whether the presence of any of the seven recurrent genomic deletions IKZF1, 
CDKN2A/2B, PAX5, BTG1, EBF1, ETV6, RB or different co-occurrences of these such 
as in Figure 2C-E had independent prognostic value in comparison to the other clinical 
co-variables described above, we performed a multivariable analyses using Cox 
proportional hazards models to assess their independent predictive power for OS, DFS 
and REM. This analysis revealed that in addition to strong clinical and therapeutic 
co-variables such as Imatinib schedule, conditioning intensity and failure to achieve 
CR after IP1, CDKN2A/2B deletions were retained as independent negative prognostic 
factors for all endpoints OS (hazard ratio 2.162, p=0.014), DFS (hazard ratio 2.621, 
p=0.0054) and REM (hazard ratio 4.066, p=0.0061) (Table 3). To further exclude that 
this independent predictive effect was based on a biased distribution or confounding 
effects by connection other variables, we correlated presence of CDKN2A/2B 
deletions with the most relevant other factors described above. Expectedly in 
accordance with the multivariable analysis, this did not yield any significant 
associations (Table 4).  
 
Discussion 
In our study, we performed a comprehensive molecular analysis of a highly 
homogeneous and well annotated patient cohort of adult Ph+ ALL patients. All patients 
received treatment according to the GMALL protocols with uniform induction and 
consolidation combined with different schedules of Imatinib followed by aSCT in CR1. 
For a full and unbiased molecular analysis we combined a global explorative SNP 
array copy number analysis with a concomitant validation of the 7 most common 
recurrent deletions in ALL by MLPA. Our discovery rate of a mean of 8.6 CNAs by SNP 
array per patient sample was in congruency with previous studies assessing CNAs in 
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ALL; Mullighan et al., 8.79 CNAs / sample,41 Okamoto et al. 7.6 CNAs / sample15 - and 
yielded similar profiles of lesions as compared to these previous studies. Interestingly, 
our SNP array analysis revealed a relatively high percentage of unbalanced BCR-ABL 
breakpoints of >40%, which is considerably more frequent than in CML, where 
deletions of the reciprocal fusion product can be found in 10 to 15% of cases.42,43 A 
recent study investigating the role of additional chromosomal abnormalities (ACA) by 
cytogenetics in adult Ph+ ALL found a lower frequency of +der(22)t(9;22) and -9/9p 
abnormalities and showed these patients as a poor risk group.24  In our hands, the 
presence of unbalanced BCR-ABL breakpoints did not have a negative effect (data not 
shown).  
Due to limited access to germline controls for validation for most of the SNP array data, 
we opted to validate the copy number data by the alternative molecular method MLPA, 
which enabled the confirmation of the 7 most common gene deletions of IKZF1, PAX5, 
CDKN2A/2B, BTG1, EBF1, ETV6 and RB1. This method had been employed as the 
sole detection method in several previous studies.22,23,28 Expectedly, this validation led 
to a confirmation of SNP array data in most cases. In a few exceptions, MLPA analysis 
led to a call of deletions, where SNP array analysis did not, i.e. leading to slightly higher 
detection rates of deletions by addition of the supplementary MLPA analysis. These 
discrepancies can be explained by the circumstance that both methods are of 
semiquantitative nature and become ambiguous when the tumor samples are 
increasingly diluted with remaining normal DNA in the sample. In the discrepant cases, 
MLPA detected deletions of the respective regions by measuring intensity ratios below 
0.7, while the deletions were not distinct or large enough to enable a positive call by the 
HMM model of the more stringent SNP array analysis with anonymous references.31 
Nevertheless, these deletions were also detectable upon visual inspection of the SNP 
array profiles even though they did not reach the threshold amplitude to result in a 
positive HMM signal. Therefore, our underlying data of the seven most frequent and 
recurrent CNAs in ALL generated by the combination of SNP array and MLPA analysis 
in this study is of higher robustness as compared to previous studies, which only 
employed either one or the other method to determine profiles of CNAs. 
Based on this high confidence data, we concentrated on integrating the 7 most 
common deletions (IKZF1, PAX5, CDKN2A/2B, BTG1, EBF1, ETV6 and RB1) with the 
clinical outcome results. Thereby, only the presence CDKN2A/2B deletions but not 
IKZF1 deletions showed to be significantly adverse for all endpoints. On one side, this 
could possibly be attributed to the higher fraction of patients with IKZF-deletions, 75% 
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in our cohort versus 50 % in the cohort of Kim et al.28 and as compared to the 
frequency of CDKN2A/2B deletions, which were more evenly distributed so that the 
prognostic value of IKZF1 deletions was weaker than that of CDKN2A/2B deletions. 
On the other hand, when considering that 65% of the samples carried more than one of 
the recurrent deletions simultaneously, IKZF1 deletions had to be interpreted in a 
cooperative context with other lesions. Samples that exclusively had IKZF1 deletions 
without any of the other deletions actually had a significantly lower risk for relapse in 
the group of patients with IKZF1 deletions (Figure 3). This was also corroborated by 
the observation that the mere numeric accumulation of any of the above described 
common deletions seemed to have a significant effect on survival and risk of relapse 
(Figure 2). Nevertheless, when subjected to a multivariable analysis in consideration 
of other prognostic markers, the numeration of genomic deletions alone did not retain 
statistical independency.  
For prediction of relapse, the treatment parameter of late Imatinib administration and 
failure to achieve CR after IP1 remained the strongest independent negative 
parameters in this cohort. In contrast, the level of MRD prior to aSCT had no significant 
impact on any of the outcome measures. While the issue of MRD pre transplant is 
controversial, with several reports showing that MRD plays a predictive role in Ph+ 
ALL,44,45 our data is in agreement with other prospective studies8 and the largest 
retrospective analysis of Ph+ALL to date,46 which clearly showed that the 
BCR-ABL1/ABL transcript ratio prior to aSCT had no impact on outcome. These data 
are also consistent with the results of a prospective study demonstrating that aSCT 
can override the otherwise adverse effect of elevated MRD.47  
Interestingly, the presence of CDKN2A/2B deletions emerged as the third and only 
other independent marker for relapse. The result was similar for disease free survival. 
There, timing of Imatinib and TBI based conditioning, which in principle was mostly 
myeloablative (MAC), were strong prognostically relevant co-variables. However, also 
CDKN2A/2B and BTG1 deletions were retained as independent molecular markers. 
For overall survival, the presence of CDKN2A/2B deletions was even the strongest 
independent adverse risk marker. In comparison to previous studies, this is a novel 
and somewhat surprising result, as we show for the first time that a molecular marker 
(genomic deletion) independently supplements or even outperforms established risk 
stratifiers in Ph+ ALL and this factor is not IKZF1. To this end, our results are largely in 
agreement with a recent study that revealed the presence of CDKN2A/2B deletions as 
determined by FISH analysis in a patient cohort of n=135 adult Ph+ ALL patients as a 
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negative predictor for survival and risk of relapse.27 Arguments possibly explaining an 
exceptionally strong role of CDKN2A/2B deletions in Ph+ ALL have been shown by 
functional biologic experiments indicating absence of gene expression from the 
CDKN2A/2B locus co-operates with the BCR-ABL oncogene to enhance the 
aggressiveness of the disease by strongly increasing the self-renewal capacity of 
leukemia cells, increasing clonal turnover and thereby conferring resistance to TKI 
therapy.48-50 Furthermore, our results are also not in disagreement with the study by 
Kim et al.28, where a negative impact of IKZF1 deletions was shown for relapse, which 
was however not retained in multivariable analysis. Furthermore, in that study, no 
comparison regarding the prognostic value of IKZF1 deletions in combination with 
other deletions was made because other lesions were not examined. 
In conclusion, in the adult Ph+ ALL cohort assessed in our study, CDKN2A/2B 
deletions for the first time emerged as a new strong and independent prognostic 
marker for predicting risk of relapse and overall survival on the background of TKI 
treatment and aSCT. In contrast, IKZF1 deletions did not prove to be a suitable marker 
because their effect was diluted by a dependency on the co-occurrence of other ALL 
typical genomic lesions. These results highly warrant the further prospective 
evaluation of ALL typical genomic deletions, especially CDKN2A/2B for risk 
stratification of adult Ph+ ALL to further improve therapeutical strategies for this high 
risk patient group. 
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Table 1: Patient characteristics 
 
Parameter (n) (%) 
Sample size 
All patients aSCT in CR1 
 
97 
 
100 
Age (years) 
Median 
Range 
 
41 
18 - 64 
 
Sex 
Male 
Female 
 
58 
39 
 
60 
40 
Breakpoint BCR-ABL 
M-Bcr-Abl (b2a2, b3a2) 
m-Bcr-Abl (e1a2) 
e1a3 / b2a3 
n.a. 
 
33 
52 
2 / 1 
9 
 
34 
54 
3 
9 
White Blood Cells (/µL) 
< 30.000 
> 30.000 
n.a. 
 
49 
46 
2 
 
51 
47 
2 
SCT donor type 
matched Sib / UD 
mismatched Sib / UD 
haplo 
n.a. 
 
72 (27 / 45) 
21 (1 / 20) 
1 
3 
 
74 
22 
1 
3 
Stem Cell Source 
PBSCT 
BM 
n.a. 
 
92 
4 
1 
 
95 
4 
1 
Conditioning Regimen 
TBI based (+Cy/+VP16/+other) 
no TBI 
n.a. 
 
80 
16 
1 
 
82 
17 
1 
Imatinib-therapy 
from Induction I  
after Induction I (day 24) 
after Induction II 
 
69 
23 
5 
 
71 
24 
5 
Early clinical response 
CR after IP1 (d26) 
No CR after IP1 (d26) 
n.a. 
 
78 
9 
10 
 
81 
9 
10 
Follow up 
Median follow up OS 
Median follow up DFS and REM 
 
35 months (5.4-114.4)  
20.5 months (0.6-108.3) 
 
 
Abbreviations: aSCT = allogeneous stem cell transplantation, CR1 = first complete 
remission, n.a. = not available, Sib = sibling, UD = unrelated donor, haplo = haploident, 
PBSCT = peripheral blood derived stem cell transplantation, BM = bone marrow 
derived stem cell transplantation, TBI = total body irradiation, Cy = Cyclophosphamide, 
VP16 = Etoposide, CR = complete remission, IP1 = induction phase 1, OS = overall 
survival, DFS = disease free survival, REM = remission duration. 
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Table 2: Recurrent genomic alterations detected by SNP-A and in combination 
with MLPA. Abbreviations: SNP-A = Single nucleotide polymorphism array, MLPA = 
Multiplex ligation-dependent probe amplification. 
 
Chromosome Genomic position Copy 
number 
Candidate 
genes 
Frequency 
(SNP-A) 
n / (%) 
Final 
frequency 
(SNP-A + 
MLPA) 
n / (%) 
7p12.2 50433798 - 50449506 0/1 IKZF1 72 / (74) 74 / (77) 
9p21.3 21976218 - 21993223 0/1 CDKN2A/B 41 / (42) 44 / (45) 
9q34.12; 
22q11.21 
t(9;22) 1/3 
Unbalanced 
BCR-ABL 
breakpoints 
40 / (41) - 
9p13.2 36920536 - 37014122 1 PAX5 39 / (40) 42 / (43) 
12q21.33 90806299 - 91060957 1 BTG1 14 / (14) 17 / (18) 
13q14.2 47885033 - 47960991 0/1 RB1 13 / (13) 14 / (14) 
21p11.2-q22.3 trisomy 21 3 - 13 / (13) - 
7p22.2-7q36.3 monosomy 7 1 - 12 / (12) - 
5q33.3 158373754- 158464289 1 EBF1 11 / (11) 12 / (12) 
15q12 23587298 - 23635904 0/1 ATP10A 11 / (11) - 
4p16.3-q35.2 trisomy 4 3 - 10 / (10) - 
14q11.2-q32.3
3 
trisomy/quatrosomy 14 3/4 - 10 / (10) - 
1q31.3 
197072462 - 
197162608 
1 
MIR181A1/B
1 
9 / (9) - 
6p25.3-q27 trisomy 6 3 - 9 / (9) - 
8p23.3-q22.3 trisomy 8 3 - 8 / (8) - 
3q13.2 
113640344 - 
113678765 
0/1 
BTLA/CD20
0 
7 / (7) - 
2q32.3 
196692024 - 
196804136 
1 
HECW2, 
STK17B 
7 / (7) - 
5p15.33-q35.3 trisomy 5 3 - 7 / (7) - 
20p12.2 10365416 - 10404586 0/1 C20orf94 6 / (6) - 
2p25.3-q37.3 trisomy 2 3 - 6 / (6)  - 
18p11.23-q23 trisomy 18 3 - 6 / (6) - 
Xp22.33-q28 trisomy/quatrosomy X 3 - 6 / (6) - 
12p13.2 11767661 - 11830795 1 ETV6 5 / (5) 5 / (5) 
17p13.3-q25.3 trisomy 17 3 - 5 / (5) - 
3p14.2 60037676 - 60351480 1 FHIT 4 / (4) - 
5q14.3 88090048 - 88251350 1 MEF2C 4 / (4) - 
10p15.3-q26.3 trisomy 10 3 - 4 / (4) - 
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Table 3: Results of multivariable analysis using Cox proportional hazards 
models. CR = complete remission, IP1 = induction phase 1, MAC = myeloablative 
conditioning / RIC = reduced intensity conditioning, TBI = total body irradiation. 
 
Endpoint Co-variable Hazard ratio p-value 
Remission duration Imatinib late schedule 7,156 <0.0001 
No CR after IP1 4,122 0.01 
CDKN2A/B deletion 4.066 0.0061 
Disease free 
survival 
Imatinib late schedule 3.148 0.0004 
TBI based conditioning 2.915 0.0087 
CDKN2A/B deletion 2.621 0.0054 
BTG1 deletion 2.060 0.047 
Overall survival CDKN2A/B deletion 2.162 0.014 
RIC versus MAC 1.934 0.069 
Imatinib late schedule 1.918 0.0429 
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Table 4: Comparison of distribution of clinical and treatment co-variables with 
the presence or absence of CDKN2A/2B deletions. (WBC = white blood cell count, 
SIB = HLA matched sibling transplantation, MUD = matched unrelated donor, TBI = 
total body irradiation, n.a. = not available)  
 
Parameter CDKN2A/B deleted 
n=44 
CDKN2A/B wildtype 
n=53 
p 
Age  
Median years; (range) 
 
41 (19-64) 
 
41 (18-60) 
 
0.72 
Sex (female / male) 16 (39%) / 28 (64%) 23 (43%) / 36 (68%) 0.074 
WBC 
Median;(range)/mm3 
n.a. 
 
41020 (800-269000)  
1 (2%) 
 
20450 (1130-250000) 
1 (2%)  
 
0.074 
Breakpoint 
    - p190BCR-ABL1 
    - p210BCR-ABL1 
    - other / n.a. 
 
21 (47%) 
16 (36%) 
3 (7%) / 2 (5%) 
 
31 (59%) 
17 (32%) 
0 / 5 (9%) 
 
0.539 
Imatinib schedule 
    - early 
    - late 
 
30 (68%) 
14 (32%) 
 
39 (74%) 
14 (26%) 0.342 
Type of HSCT 
- SIB  
- MUD  
- n.a. 
 
12 (27%) 
32 (73%) 
 
18 (34%) 
34 (64%) 
1 (2%) 
0.598 
Conditioning 
regimen 
- TBI-based  
- no TBI 
- n.a. 
 
 
36 (82%) 
8 (18%) 
 
 
44 (83%) 
8 (15%) 
1 (2%) 
0.134 
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Figure legends 
 
Figure 1: Univariate outcome data: Outcome in dependency of presence of 
CDKN2A/2B deletions, (A) overall survival (OS), (B) disease free survival (DFS), (C) 
remission duration (REM). Outcome in dependency of presence of IKZF1 deletions, 
(D) OS, (E) DFS, (F) REM. 
 
Figure 2: Univariate outcome data in dependency of the numeric accumulation 
of the seven most recurrent deletions (IKZF1, PAX5, CDKN2A/2B, BTG1, EBF1, 
ETV6 and RB1): (A) Proportionate distribution of the number concomitant recurrent 
deletions over all samples, (B) Outcome of disease free survival (DFS) in dependency 
of the number of the above described deletions, (C-E) Outcome data in dependency of 
the presence of 0 or 1 deletion versus 2 or more (C) overall survival (OS), (D) DFS, (E) 
REM, (F) leucocyte count in dependency of the number of deletions. 
 
Figure 3: Univariate outcome data in patients with IKZF1 deletions: (A) disease 
free survival and (B) remission duration in dependency of exclusive IKFZ1 deletions 
versus IKZF1 deletions in combination with other recurrent deletions. 
 
Figure 4: Univariate outcome data in dependency of Imatinib scheduling: (A) 
Overall survival, (B) disease free survival, (C) remission duration and conditioning 
intensity (MAC = myeloablative conditioning, RIC = reduced intensity conditioning), (D) 
overall survival, (E) disease free survival, (F) Remission duration. 
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